¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oculocutaneous telangiectasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oculocutaneous
    ´«ÇǺÎ-
  • oculocutaneous albinism
    ´«ÇǺιé»öÁõ
  • oculocutaneous nevus
    ´«ÇǺθð¹Ý
  • oculocutaneous tyrosinemia
    ´«ÇǺÎÇüƼ·Î½ÅÇ÷Áõ
  • ataxia telangiectasia
    ¸ð¼¼°üÈ®Àå½ÇÁ¶
  • essential telangiectasia
    º»Å¸ð¼¼Ç÷°üÈ®Àå(Áõ)
  • hereditary hemorrhagic telangiectasia
    À¯Àü¼ºÃâÇ÷¸ð¼¼Ç÷°üÈ®ÀåÁõ
  • periungual telangiectasia
    ¼Õ¹ßÅéÁÖÀ§¸ð¼¼Ç÷°üÈ®Àå(Áõ)
  • spider telangiectasia
    °Å¹Ì¸ð¼¼Ç÷°üÈ®Àå(Áõ)
  • telangiectasia
    ¸ð¼¼Ç÷°üÈ®Àå(Áõ)
  • unilateral nevoid telangiectasia
    ÀÏÃø¸ð¹Ý¸ð¼¼Ç÷°üÈ®Àå(Áõ)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • telangiectasia
    ¸ð¼¼Ç÷°üÈ®Àå, ½ÇÇÍÁÙÈ®Àå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oculocutaneous albinism
    ´«ÇǺιé»öÁõ
  • oculocutaneous nevus
    ´«ÇǺθð¹Ý
  • oculocutaneous tyrosinemia
    ´«ÇǺÎÇüƼ·Î½ÅÇ÷Áõ
  • ataxia telangiectasia
    ¸ð¼¼Ç÷°üÈ®À强Á¶È­¿îµ¿ºÒ´É
  • arborizing telangiectasia
    ºÐÁö¸ð¼¼Ç÷°üÈ®ÀåÁõ, °¡Áö½ÇÇÍÁÙÈ®ÀåÁõ
  • essential telangiectasia
    º»Å¸ð¼¼Ç÷°üÈ®ÀåÁõ,
  • hereditary hemorrhagic telangiectasia
    À¯ÀüÃâÇ÷¸ð¼¼Ç÷°üÈ®ÀåÁõ, À¯ÀüÃâÇ÷½ÇÇÍÁÙÈ®ÀåÁõ
  • periungual telangiectasia
    ¼Õ¹ßÅéÁÖÀ§¸ð¼¼Ç÷°üÈ®ÀåÁõ
  • spider telangiectasia
    (¢¡spider telangiectasis) °Å¹Ì¸ð¼¼Ç÷°üÈ®ÀåÁõ, °Å¹Ì½ÇÇÍÁÙÈ®ÀåÁõ
  • telangiectasia
    ½ÇÇÍÁÙÈ®ÀåÁõ, ¸ð¼¼Ç÷°üÈ®ÀåÁõ
  • telangiectasia
    Âü½ÇÇÍÁÙÈ®ÀåÁõ
  • unilateral nevoid telangiectasia
    ÀÏÃø¸ð¹Ý¸ð¼¼Ç÷°üÈ®ÀåÁõ, ÇÑÂʸð¹Ý½ÇÇÍÁÙÈ®ÀåÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hermansky-Pudlak syndrome => oculocutaneous albinism
    ¾È±¸ ÇǺΠ¹é»öÁõ
  • CRST(Calcinosis, Raynauds phenomenon, Sclerodactyly, Telangiectasia) syndrome
    CRST ÁõÈıº.
  • arborizing telangiectasia
    ºÐÁö ¸ð¼¼Ç÷°ü È®Àå
  • generalized essential telangiectasia
    Àü½Å¼º º»Å¼º ¸ð¼¼Ç÷°ü È®Àå(Áõ)
  • hereditary hemorhagic telangiectasia(osler-weber-rendu disease,)
    À¯Àü¼ºÃâÇ÷¼º¸ð¼¼Ç÷°ü È®Àå
  • hereditary hemorrhagic telangiectasia
    À¯Àü(¼º) ÃâÇ÷¼º ¸ð¼¼(Ç÷)°üÈ®Àå.
  • hereditary hemorrhagic telangiectasia
    À¯Àü¼º ÃâÇ÷ Ç÷°üÈ®Àå
  • pregnancy,spider telangiectasia
    °Å¹Ì¸ð¾çÇ÷°üÈ®ÀåÁõ(¸ð¼¼Ç÷°üÈ®ÀåÁõ)(¡­Ù¼åÆúìηüªíåñø(Ù¾á¬úìηüªíåñø))
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oculocutaneous telangiectasia
    ¾ÈÇǺθð¼¼Ç÷°üÈ®ÀåÁõ(äÑù«Ý±Ù¾á¬úìηüªíåñø)
  • oculocutaneous telangiectasia
    ¾ÈÇǺθð¼¼Ç÷°üÈ®Àå
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oculocutaneous albinism
    ´« ÇǺΠ¹é»öÁõ
  • oculocutaneous albinism
    ¾ÈÇǺÎÇü¹é»öÁõ(äÑù«Ý±û¡ÛÜßäñø).
  • oculocutaneous albinism
    ´«ÇǺιé»öÁõ, ¾ÈÇǺιé»öÁõ(äÑù«Ý±ÛÜßäñø)
  • oculocutaneous nevi
    ´«ÇǺΠ¸ð¹Ý
  • arborizing telangiectasia
    ºÐÁö ¸ð¼¼Ç÷°ü È®Àå
  • ataxia telangiectasia
    Ç÷°üÈ®À强 ¿îµ¿½ÇÁ¶Áõ.
  • ataxia telangiectasia
    ¸ð¼¼Ç÷°üÈ®À强(Ç÷°üÈ®À强) ¿îµ¿½ÇÁ¶Áõ(Ù½á¬úìηüªíåàõê¡ÔÑã÷ðàñø)
  • ataxia-telangiectasia
    Ç÷°üÈ®À强 ¿îµ¿½ÇÁ¶Áõ
  • ataxia-telangiectasia
    ¸ð¼¼Ç÷°üÈ®À强¿îµ¿½ÇÁ¶
  • essential telangiectasia
    º»Å¼º(Üâ÷¾àõ) ¸ð¼¼Ç÷°ü È®Àå
  • familial telangiectasia
    °¡Á·¼º ¸ð¼¼Ç÷°ü È®Àå
  • generalized essential telangiectasia
    Àü½Å¼º º»Å¼º ¸ð¼¼Ç÷°ü È®Àå(Áõ)
  • hereditary hemorhagic telangiectasia(osler-weber-rendu disease,)
    À¯Àü¼ºÃâÇ÷¼º¸ð¼¼Ç÷°ü È®Àå
  • hereditary hemorrhagic telangiectasia
    À¯Àü¼º ÃâÇ÷ Ç÷°üÈ®Àå
  • hereditary hemorrhagic telangiectasia
    À¯Àü(¼º) ÃâÇ÷¼º ¸ð¼¼(Ç÷)°üÈ®Àå.
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hereditary hemorrhagic telangiectasia
    À¯Àü¼ºÃâÇ÷¼º¸ð¼¼Ç÷°üÈ®Àå
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
OCA oculocutaneous albinism; olivopontocerebellar atrophy; oral contraceptive agent
CREST Syndrome   1. Calcinosis cutis
  2. Raynaud's phenomenon
  3. Esophageal ...
CRST Syndrome   1. Calcinosis
  2. Raynaud's Phenomenon
  3. Sclerodactyly
...
A-T ataxia telangiectasia
CREST calcinosis, Raynaud phenomenon, esophageal involvement, sclerodactyly, and telangiectasia [syndrome]...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
OCA Oculocutaneous albinism
ATM Ataxia Telangiectasia Mutated
HHT Hereditary Haemorrhagic Telangiectasia
HHT1 Hereditary Haemorrhagic Telangiectasia Type 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oculocutaneous
    ¾È ÇǺÎÀÇ
    ´«°ú ÇǺο¡ ¸ðµÎ ÀÌȯµÈ.
  • hereditary telangiectasia
    À¯Àü¼º ¸ð¼¼Ç÷°ü È®ÀåÁõ
    ¼±ÃµÀûÀ¸·Î ¸ð¼¼Ç÷°üÀÌ È®ÀåµÇ´Â ÁúȯÀ¸·Î °üÂû ½Ã ¹ÝÁ¡»ó È«¹ÝÀ¸·Î ³ªÅ¸³ª°í °³º°ÀûÀ¸·Î È®ÀåµÈ Ç÷°ü ¾ç»óÀ» °üÂûÇÒ ¼ö ÀÖ´Ù.
  • telangiectasia
    ¸ð¼¼°ü È®ÀåÁõ, ¸ð¼¼Ç÷°ü È®ÀåÁõ
    µ¿ÀǾî=telagiectasis. 1. ÀÌ¹Ì Á¸ÀçÇÏ´Â Ç÷°ü
  • telangiectasia papulosa disseminata µ¿ÀǾî=cherry hemangioma.

    telangiectasis

    ¸ð¼¼Ç÷°ü È®ÀåÁõ, ¸»ÃÊÇ÷°ü È®Àå
    ¸ð¼¼°ü¸Æ ¶Ç´Â Á¾¸» µ¿¸ÆÀÇ È®Àå¿¡ ÀÇÇØ¼­ Çü¼ºµÇ´Â ¹ÝÁ¡À¸·Î¼­ ¸¹Àº °ÍÀº ÇǺο¡ ¹ßÇöµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cephalo-oculocutaneous telangiectasia An angioma involving the skin of the face, orbit, meninges, and brain.
See: Sturge-Weber syndrome.
(05 Mar 2000)
albinism, oculocutaneous Heterogeneous group of autosomal recessive disorders comprising at least four recognised types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. The two most common are the tyrosinase-positive and tyrosinase-negative types.
(12 Dec 1998)
oculocutaneous Relating to the eyes and the skin.
(05 Mar 2000)
oculocutaneous albinism An autosomal recessive deficiency of pigment in skin, hair, and eyes; in the tyrosinase negative type, there is an absence of tyrosinase; in the tyrosinase positive type, there is normal tyrosinase which cannot enter pigment cells; it is transmitted by an autosomal recessive inheritance. The compound heterozygote is normal so the two forms are not allelic.
There are several types: type IA is characterised by absence of tyrosinase with life-long complete absence of melanin, marked photophobia, and nystagmus. Type IB, yellow albinism with low or absent tyrosinase; improves with age.
Type II, with normal tyrosinase activity is the most common; hair darkens and nevi and freckles develop.
Type III is characterised by absent tyrosinase but pigmentation of the iris in the first decade.
Type IV in Africans with normal tyrosinase.
Type V with red hair.
Type VI, Hermansky-Padlak syndrome, with haemorrhage due to platelet deficiency and low to absent tyrosinase.
Synonym: Hermansky-Pudlak syndrome type VI.
(05 Mar 2000)
oculocutaneous syndrome <syndrome> Bilateral uveitis with iritis and glaucoma, premature graying of the hair, and alopecia, vitiligo, and dysacusia; related to Harada's syndrome and sympathetic ophthalmia.
Synonym: oculocutaneous syndrome, uveocutaneous syndrome.
Origin: Cecile and Oscar Vogt
(05 Mar 2000)
ataxia-telangiectasia <neurology, oncology> An intriguing autosomal recessive disorder in which a single defective gene produces myriad and protean effects, presents with cerebellar ataxia, telangiectasias in the eyes and skin, immune deficiency and autoimmune phenomena, propensity for lymphoid and other malignancies, excessive sensitivity to ionising radiation, increased serum alpha-fetoprotein concentrations and a tendency for chromosome breakage and translocation.
A syndrome characterised by choreoathetosis beginning in childhood, progressive cerebellar ataxia, telangiectasis of conjunctiva and skin, slowly progressive mental deterioration and increasing cerebellar degeneration.
There is evidence that heterozygotes show an increased susceptibility to malignancy as well, with breast cancer often cited. The gene was localised by linkage studies to chromosome 11q22-23, and recently cloned, revealing it to be homologous to the PI-3 kinase family so that prenatal diagnosis by RFLP analysis is possible.
Other related genes are suspected to exist. Diagnosis in affected patients is made on clinical grounds, by detection of high concentrations of alpha-fetoprotein, and by a specialised cell culture assay for radiosensitivity and atypical radioresistant DNA synthesis. These cell culture methods are also used for prenatal diagnosis.
A characteristic autopsy feature of ataxia-telangiectasia is the presence of empty basket cells in the cerebellum which results from degeneration of the previously contained Purkinje cells.
Inheritance: autosomal recessive.
(16 Dec 1998)
ataxia telangiectasia syndrome ataxia telangiectasia
primary telangiectasia angioma serpiginosum
hereditary haemorrhagic telangiectasia <gastroenterology> An inherited disease characterised by thin blood vessel walls in the nose, skin and gastrointestinal tract. This condition ins associated with a high risk of bleeding complications.
Inheritance: autosomal dominant.
(27 Sep 1997)
secondary telangiectasia Telangiectasia related to a known cause of prolonged dermal vascular dilatation such as sunlight, varicose veins, and connective tissue diseases; often associated with atrophy of the skin.
(05 Mar 2000)
spider telangiectasia spider angioma
telangiectasia <clinical sign> A permanent dilation of preexisting blood vessels (capillaries, arterioles, venules), creating small focal red lesions, usually in the skin or mucous membranes. Also called telangiectasis.
(16 Dec 1997)
telangiectasia, hereditary haemorrhagic An autosomal dominant vascular anomaly characterised by the presence of multiple small telangiectases of the skin, mucous membranes, gastrointestinal tract, and other organs, associated with recurrent episodes of bleeding from affected sites and gross or occult melena.
(12 Dec 1998)
telangiectasia lymphatica Dilatation of the lymphatic vessels.
(12 Dec 1998)
telangiectasia macularis eruptiva perstans A disseminated eruption of telangiectases associated with erythematous and edematous macules.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á